Mayne Pharma Group (ASX:MYX) said the acquisition of 100% shares in the firm by Cosette Pharmaceuticals is now expected to close in late June to early July, according to a Tuesday Australian bourse filing.
It also signed an agreement with Sol-Gel Technologies to acquire and exclusively license the US rights to TWYNEO, a tretinoin and benzoyl peroxide cream for the treatment of acne vulgaris, and EPSOLAY, for the treatment of inflammatory lesions of rosacea.
The terms of the agreement are $10 million in cash at closing and an additional $6 million in cash six months after closing.
The underlying losses before interest, taxes, depreciation, and amortization for the fiscal third quarter ended March came in at AU$3.4 million, while net sales for the period came in at AU$86.8 million, down 11.3% on the same period in the previous year.
The firm expects to report underlying EBITDA in the range of AU$47 million to AU$51 million for the fiscal year, rising 105% to 123% from the fiscal year 2024.
Price (AUD): $7.05, Change: $+0.060, Percent Change: +0.86%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。